Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Lithium Ion. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY5R | Q15761 | 18/20 | 0.52 |
| ▸ | GRM5 | P41594 | 2/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.37 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Lithium Ion SCHEMBL2999454 | 1.00 | NPY5R (0.52) | NPY5RGRM5KCNH2ADRA1A | |
| SCHEMBL3754556 | 0.89 | NPY5R (0.54) | NPY5RGRM5 | |
| SCHEMBL3004620 | 0.89 | NPY5R (0.54) | NPY5RGRM5 | |
| SCHEMBL3004622 | 0.89 | NPY5R (0.54) | NPY5RGRM5 | |
| SCHEMBL13045661 | 0.82 | NPY5R (0.52) | NPY5RGRM5KCNH2ADRA1A | |
| SCHEMBL3741649 | 0.82 | NPY5R (0.61) | NPY5RGRM5 | |
| SCHEMBL3741651 | 0.82 | NPY5R (0.61) | NPY5RGRM5 | |
| Lithium Ion SCHEMBL3021432 | 0.81 | NPY5R (0.52) | NPY5RGRM5KCNH2ADRA1A | |
| SCHEMBL13728908 | 0.81 | NPY5R (0.55) | NPY5RGRM5KCNH2ADRA1A | |
| SCHEMBL3738915 | 0.81 | NPY5R (0.55) | NPY5RGRM5KCNH2ADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100197699-A1 | I-OXA-3-Azaspiro (4.5) Decan-2-One And 1-OXA-3, 8-Diazaspiro (4.5) Decan-2-One Derivatives For The Treatment of Eating Disorders | GLAXO GROUP LIMITED | 2010-08-05 | — | — | US | disclosed |
| EP-2121673-A1 | I-OXA-3-AZASPIRO (4.5) DECAN-2-ONE AND 1-OXA-3, 8-DIAZASPIRO (4.5) DECAN-2-ONE DERIVATIVES FOR THE TREATMENT OF EATING DISORDERS | Glaxo Group Limited (GB) | 2009-11-25 | — | — | EP | disclosed |
| WO-2008092887-A1 | I-OXA-3-AZASPIRO (4.5) DECAN-2-ONE AND 1-OXA-3, 8-DIAZASPIRO (4.5) DECAN-2-ONE DERIVATIVES FOR THE TREATMENT OF EATING DISORDERS | GLAXO GROUP LIMITED (GB) | 2008-08-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100197699-A1 | I-OXA-3-Azaspiro (4.5) Decan-2-One And 1-OXA-3, 8-Diazaspiro (4.5) Decan-2-One Derivatives For The Treatment of Eating Disorders | NPY5R, NPY1R, NPY4R | NPY5R 1/4885GRM5 163/4885KCNH2 1468/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.